The use of viral vectors for inner ear gene therapy is receiving increased attention for
treatment of genetic hearing disorders. Most animal studies to date have injected viral …

Inner ear gene therapy using adeno-associated viral vectors (AAV) promises to alleviate
hearing and balance disorders. We previously established the benefits of Anc80L65 in …

Cochlear gene therapy holds promise for the treatment of genetic deafness. Assessing its
impact in adult murine models of hearing loss, however, has been hampered by technical …

Efforts to develop gene therapies for hearing loss have been hampered by the lack of safe,
efficient, and clinically relevant delivery modalities,. Here we demonstrate the safety and …

Gene therapy strategies using adeno-associated virus (AAV) vectors to treat hereditary
deafnesses have shown remarkable efficacy in some mouse models of hearing loss. Even …

Adeno-associated virus (AAV) has been successfully used to deliver gene therapy to
improve auditory function in mouse models of hereditary hearing loss. Many forms of …

In a number of mouse models of hereditary deafness, therapeutic transgene delivery to the
cochlea and vestibular organs using adeno-associated viral vectors (AAVs) has shown …

Hearing loss, including genetic hearing loss, is one of the most common forms of sensory
deficits in humans with limited options of treatment. Adeno-associated virus (AAV)-mediated …

Congenital hearing deficits can be caused by a variety of genetic and acquired conditions.
Complete reversal of deficits in the peripheral auditory system may require delivery of …

The cochlea consists of multiple types of cells, including hair cells, supporting cells and
spiral ganglion neurons, and is responsible for converting mechanical forces into electric …